Nkgen Biotech, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Meteora Capital, LLC and its managing member Vik Mittal have disclosed a 6.13% beneficial ownership stake in NKGen Biotech, Inc., held in the ordinary course of business.
OTC.Pink
Pathstone Family Office, LLC has filed a Schedule 13G, reporting beneficial ownership of 7.91% of NKGen Biotech, Inc.'s common stock as of October 17, 2024.
OTC.Pink
Meteora Capital, LLC and its Managing Member Vik Mittal have disclosed a beneficial ownership of 7.84% in NKGen Biotech, Inc.'s common stock as of December 31, 2024.